PHAT 12.00 ▲ 1.01% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Phathom Pharmaceuticals I...

    NASDAQ: PHAT · Real-Time Price · USD
    12.00
    0.12 (1.01%)
    At close: Sep 04, 2025, 3:59 PM
    11.94
    -0.50%
    After-hours: Sep 04, 2025, 07:15 PM EDT
    1.01%
    Bid 12
    Market Cap 851.32M
    Revenue (ttm) 114.04M
    Net Income (ttm) -330.15M
    EPS (ttm) -4.67
    PE Ratio (ttm) -2.57
    Forward PE -38.23
    Analyst Buy
    Ask 12.19
    Volume 1,654,955
    Avg. Volume (20D) 2,325,995
    Open 11.98
    Previous Close 11.88
    Day's Range 11.25 - 12.03
    52-Week Range 2.21 - 19.71
    Beta 0.45

    About PHAT

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol PHAT
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for PHAT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Phathom Pharmaceuticals Inc. is scheduled to release its earnings on Nov 6, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    3 months ago
    +90.19%
    Phathom Pharmaceuticals shares are trading higher ... Unlock content with Pro Subscription
    4 months ago
    -17.86%
    Phathom Pharmaceuticals shares are trading lower after HC Wainwright maintained a Buy rating on the stock and lowered its price target from $28 to $20.
    news image

    1 week ago · zacks.com

    Wall Street Analysts Think Phathom Pharmaceuticals (PHAT) Could Surge 87.21%: Read This Before Placing a Bet

    The consensus price target hints at an 87.2% upside potential for Phathom Pharmaceuticals (PHAT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in e...

    news image

    4 weeks ago · seekingalpha.com

    Phathom Pharmaceuticals, Inc. (PHAT) Q2 2025 Earnings Call Transcript

    Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Eric Sciorilli - Corporate Participant Robert Breedlove - VP of Finance & P...

    news image

    4 weeks ago · zacks.com

    Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates

    Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to a loss of $1.25 per share a year ago.

    news image

    2 months ago · seekingalpha.com

    Phathom Pharmaceuticals: Potential Blockbuster Gastric Acid-Reducing Drug With New Mechanism

    VOQUEZNA's FDA exclusivity through 2032 and superior efficacy in GERD and H. pylori create a strong competitive moat in a $3.2B+ market. Rapid commercial uptake, robust DTC marketing, and >80% insuran...

    news image

    2 months ago · seekingalpha.com

    Tiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: Buy

    I'm bullish on Phathom Pharmaceuticals, Inc. after the FDA granted 10-year exclusivity to their flagship GI drug, Voquezna, giving them near-monopoly status. For those who don't know, this is a big de...

    news image

    2 months ago · zacks.com

    Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade

    The consensus price target hints at a 107.4% upside potential for Phathom Pharmaceuticals (PHAT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in e...

    news image

    3 months ago · https://thefly.com

    Phathom Pharmaceuticals price target raised by $6 at Cantor Fitzgerald, here's why

    19 Aug

    Add to Watchlist